Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data

Nezka Hribernik; Rozala Arko; Gorana Gasljevic; Martina Rebersek

doi:10.2478/raon-2026-0020

.blurhash-client-img { display: none !important; }

Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data

Radiology and Oncology

AHEAD OF PRINT

By: Nezka Hribernik, Rozala Arko, Gorana Gasljevic and Martina Rebersek

Open Access

|Apr 2026

Abstract

Background

Adjuvant nivolumab has become the new standard of care for patients with oesophageal and gastroesophageal junction cancer (OEC/GEJC) following neoadjuvant chemoradiotherapy (neoCRT) and surgical resection. In Slovenia, this treatment has been in use since January 2022. Here, we report the first Slovenian real-world experience with adjuvant nivolumab.

Patients and methods

We conducted a retrospective, observational cohort study of patients with OEC/GEJC who received adjuvant nivolumab after neoCRT and radical resection between January 2022 and December 2023. Data on patient characteristics, treatment completion, disease progression, and immune-related adverse events (irAEs) were collected from medical records and analysed via descriptive statistics.

Results

A total of 17 patients were included. The median follow-up was 34.6 months (range 11.2–55.7). The cohort included 14 (82%) males, with a mean age of 59 years. The Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 15 (88%) patients and 1 for 2 (12%) patients. The tumor location was the esophagus in 9 (53%) patients and the gastroesophageal junction in 8 (47%) patients. At diagnosis, 13 (76%) patients were stage III (8th TNM classification). Histology revealed adenocarcinoma (AC) in 12 (71%) patients and squamous cell carcinoma (SCC) in 5 (29%) patients. Only 6 (35%) patients completed one year of adjuvant nivolumab. Treatment was discontinued in 5 (29%) patients due to disease progression and in 6 (35%) patients due to irAEs. Overall, 11 (65%) patients experienced irAEs of any grade. Grade 3 or 4 irAEs occurred in 4 (24%) patients: myocarditis G4 in 1 (6%) patient and colitis G3 in 3 (18%) patients. No irAE-related deaths were reported. The median disease-free survival (DFS) was 21.4 months (95% confidence interval [CI], 14.6–28.9).

Conclusions

Real-world data from Slovenia indicate that 65% of patients discontinued adjuvant nivolumab prematurely due to disease progression or irAEs. These findings highlight the need for careful patient selection and monitoring when using adjuvant immunotherapy in this population.

References

World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. [internet]. [cited 2025 Sept 19]. Available at: http://globocan.iarc.fr
Search in Google Scholar Back to article
Cancer in Slovenia 2021. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2024
Search in Google Scholar Back to article
Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 9921004. doi: 10.1016/j.annonc.2022.07.003
Open DOI Search in Google Scholar Back to article
Secerov-Ermenc A, Peterlin P, Anderluh F, But-Hadzic J, Jeromen-Peressutti A, Velenik V, et al. Interobserver variation in gross tumour volume delineation of oesophageal cancer on MR, CT and PET/CT. Radiol Oncol 2024; 58: 580-7. doi: 10.2478/raon-2024-0043
Open DOI Search in Google Scholar Back to article
Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al; CROSS Study Group. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The Randomized Controlled CROSS Trial. J Clin Oncol 2021; 39: 1995-2004. doi: 10.1200/JCO.20.03614
Open DOI Search in Google Scholar Back to article
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al; CheckMate 577 investigators. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021; 384: 1191-203. doi: 10.1056/NEJMoa2032125. Erratum in: N Engl J Med 2023; 388: 672. doi: 10.1056/NEJMx220014
Open DOI Search in Google Scholar Back to article
Kelly RJ, Ajani JA, Kuzdazal J, Zander T, Can Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): first results of overall survival (OS) from CheckMate 577. [Abstract]. 2025 ASCO Annual Meeting. J Clin Onco 2025; 43(16 Suppl). doi: 10.1200/JCO.2025.43.16suppl.4000
Open DOI Search in Google Scholar Back to article
Kwak HV, Banks KC, Hung YY, Alcasid NJ, Susai CJ, Patel A, et al. Adjuvant immunotherapy in curative intent esophageal cancer resection patients: real-world experience within an integrated health system. Cancers (Basel) 2023; 15: 5317. doi: 10.3390/cancers15225317
Open DOI Search in Google Scholar Back to article
Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, et al; ESMO Guidelines Committee. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol 2022; 33: 878-92. doi: 10.1016/j.annonc.2022.04.007
Open DOI Search in Google Scholar Back to article
Brunelli C, Zito E, Alfieri S, Borreani C, Roli A, Caraceni A, et al. Knowledge, use and attitudes of healthcare professionals towards patient-reported outcome measures (PROMs) at a comprehensive cancer center. BMC Cancer 2022; 22: 161. doi: 10.1186/s12885-022-09269-x
Open DOI Search in Google Scholar Back to article
Tarazona N, Gimeno-Valiente F, Cervantes A. Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible. ESMO Open 2022; 7: 100547. doi: 10.1016/j.esmoop.2022.100547
Open DOI Search in Google Scholar Back to article
Hoeppner J, Brunner T, Schmoor C, Bronsert P, Kulemann B, Claus R, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med 2025; 392: 323-35. doi: 10.1056/NEJMoa2409408. PMID: 39842010
Open DOI Search in Google Scholar Back to article
Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gas-tro-oesophageal junction adenocarcinoma (FLOT4): a randomized, phase 2/3 trial. Lancet 2019; 393: 1948-57. doi: 10.1016/S0140-6736(18)32557-1
Open DOI Search in Google Scholar Back to article
Obermannová RL, Leong T; ESMO Guidelines Committee. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open 2025; 10: 104134. doi: 10.1016/j.esmoop.2025.104134
Open DOI Search in Google Scholar Back to article
Janjigian YY, Al-Batran SE, Wainberg ZA, Muro K, Molena D, Van Cutsem E, et al; MATTERHORN Investigators. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med 2025; 393: 217-30. doi: 10.1056/NEJMoa2503701
Open DOI Search in Google Scholar Back to article
Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage iii melanoma. N Engl J Med 2024; 391: 1696-708. doi: 10.1056/NEJMoa2402604
Open DOI Search in Google Scholar Back to article
Kust D, Murgic J, Vukovic P, Kruljac I, Prpic M, Zilic A, et al. Oncologist burnout syndrome in Eastern Europe: results of the multinational survey. JCO Oncol Pract 2020; 16: e366-76. doi: 10.1200/JOP.19.00470
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.2478/raon-2026-0020 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Submitted on: Oct 2, 2025

Accepted on: Dec 2, 2026

Published on: Apr 16, 2026

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

oesophageal and gastroesophageal junction cancer,

adjuvant immunotherapy,

Related subjects:

Haematology, oncology,

Radiology

© 2026 Nezka Hribernik, Rozala Arko, Gorana Gasljevic, Martina Rebersek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.

AHEAD OF PRINT